|
ZHEJIANG HISUN PHARMACEUTICAL CO.,LTD.
|
Orlistat has sufficient production capacity for stable supply and has passed EU and CDE reviews. As a comprehensive pharmaceutical enterprise with complete research, production and marketing value chain and multi-region development, Hisun Pharmaceutical owns three major production bases of APIs, with perfect production lines covering nearly 100 varieties, and is one of the important producers of speciality APIs in the world.
Hisun Pharmaceutical is equipped with advanced production equipment and facilities and testing instruments, and its production, testing and release follow the requirements of GMP; Hisun Pharmaceutical has a central research institute at its headquarters in Taizhou, a nationally-recognised enterprise technology centre, a provincial academician's workstation, and the first postdoctoral scientific research station in the province with independent enrolment qualification; the R&D platform is equipped with a R&D laboratory and a small and medium-sized pilot plant, which provides seamless linkage between the development and industrialisation of new products and new processes. The R&D platform is equipped with R&D laboratories and small and medium-sized pilot production workshops, providing a seamless connection from new product and process development to industrialisation.
Hisun Pharmaceutical is equipped with a professional quality management team and a perfect quality management system, covering the whole life cycle of drug quality;
The pharmaceutical administration system of Hisun Pharmaceutical can efficiently support the global registration affairs of customers and provide better products and services for global customers;
Hisun Pharmaceutical establishes an EHS laboratory, equipped with a professional research team and advanced experimental equipment, a perfect EHS integrated management system and a professional EHS management team to escort the company's safe production and green development. The laboratory management system passed CNAS certification in 2018.
Hisun Pharmaceutical adheres to the development concept of "no best, only better", and looks forward to working with you hand in hand! |
Send Inquiry
|
|
Lunan Pharmaceutical Group Corporation
|
It is marketed as a prescription drug under the trade name Xenical by Roche in most countries, and is sold over-the-counter as Alli[2] by GlaxoSmithKline in the United Kingdom and the United States.[3] Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.[4]
|
Send Inquiry
|
|
Beijing Global Biologicals Co.Ltd
|
96829-58-2 Weight- Loss Product Orlistat
Specification:
Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as aprescription drug under the trade name Xenical by Roche in most countries, and is sold over-the-counter as Alli by GlaxoSmithKline in the United Kingdom and the United States. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.
The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trialssuggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4.4–6.6 lb) more than those not taking the drug over the course of a year. Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.
Company Shows
|
Send Inquiry
|
Pharma Sources Insight June 2024: Globalization on the Go
